Connect your AI

Alamar Biosciences ALMR Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

Axcelis TechnologiesACLS

-$39K-106%

Hims & Hers HealthHIMS

$242K-65.1%

First American FinancialFAF

$12.8M+28.0%

SentinelOneS

$753K-72.9%

Nuvalent, Inc.NUVL

$1.83M-57.3%

Axis Capital HoldersAXS

$9.68M-8.8%

Other financials

Income statement

Revenue$26.0M+98.9%

Gross profit$14.5M+126%

Operating income-$12.3M-44.4%

Net income-$21.3M-178%

EPS (diluted)-$1.74-156%

Balance sheet

Cash & equivalents$64.6M—

Total debt$30.6M—

Total equity-$178.1M—

Total assets$186.5M—

Cash flow

Operating cash flow-$20.3M-55.7%

CapEx$600.0K+8.3%

Free cash flow-$20.9M-53.8%

Valuation

Market cap$1.52B—

Enterprise value$1.49B—

Returns & leverage

Debt / equity-0.2×—

Current ratio5.9×—

Where this comes from

Reported directly by Alamar Biosciences in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The official record: Alamar Biosciences ’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alamar Biosciences 's accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Alamar Biosciences 's accretion (amortization) of discounts and premiums, investments?: Alamar Biosciences (ALMR) reported accretion (amortization) of discounts and premiums, investments of $208K in Q1 2025.